Company Filing History:
Years Active: 2016
Title: Lesley Walton: Innovator in mGlu2 Receptor Agonists
Introduction
Lesley Walton is a notable inventor based in Berkshire, GB. He has made significant contributions to the field of pharmacology, particularly in the development of novel compounds for mental health treatment. His work focuses on creating innovative solutions for complex disorders.
Latest Patents
Walton holds a patent for "Bicyclo (3.1.0) hexane-2, 6-dicarboxylic acid derivatives as mGlu2 receptor agonist." This invention provides novel mGlu2 agonists that are useful in the treatment of bipolar disorder, schizophrenia, and generalized anxiety disorder. The patent highlights the potential of these compounds to improve therapeutic outcomes for patients suffering from these conditions. He has 1 patent to his name.
Career Highlights
Lesley Walton is currently associated with Eli Lilly and Company, a leading global pharmaceutical company. His role involves research and development of innovative therapeutic agents. Walton's expertise in receptor pharmacology has positioned him as a key contributor to advancements in mental health treatments.
Collaborations
Walton has collaborated with notable colleagues, including Teresa Tse Ki Man and James Allen Monn. These partnerships have fostered a collaborative environment that enhances the research and development process.
Conclusion
Lesley Walton's contributions to the field of pharmacology, particularly through his patent on mGlu2 receptor agonists, demonstrate his commitment to advancing mental health treatment. His work at Eli Lilly and Company continues to pave the way for innovative solutions in healthcare.